Clinical Trials Logo

Multiple Myeloma in Relapse clinical trials

View clinical trials related to Multiple Myeloma in Relapse.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05191472 Terminated - Multiple Myeloma Clinical Trials

Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies

Start date: May 3, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial tests whether pembrolizumab works to shrink tumors in patients with multiple myeloma whose cancer has come back (relapsed) or did not respond to previous treatment (refractory) with anti-BCMA CAR-T therapies. Immunotherapy with pembrolizumab, may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread.

NCT ID: NCT03687125 Terminated - Clinical trials for Multiple Myeloma in Relapse

Tinostamustine Conditioning and Autologous Stem Cell

TITANIUM1
Start date: October 15, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Phase 1 The primary objectives of Phase 1 of this study are to: - Establish the safety, toxicity, and maximum tolerated dose (MTD) of the tinostamustine conditioning regimen. - Identify the recommended Phase 2 dose (RP2D) of tinostamustine for use in the Phase 2 portion of the study. The secondary objective of Phase 1 of this study is to: - Investigate the pharmacokinetics (PK) of tinostamustine.

NCT ID: NCT03266692 Terminated - Multiple Myeloma Clinical Trials

Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma

Start date: February 22, 2018
Phase: Phase 1
Study type: Interventional

This is a phase 1, multi-center, single-arm, open-label study evaluating the safety, tolerability, and anti-myeloma activity of ACTR087 (an autologous T cell product) in combination with SEA-BCMA (a monoclonal antibody) in subjects with relapsed or refractory Multiple Myeloma.

NCT ID: NCT01889420 Terminated - Clinical trials for Multiple Myeloma in Relapse

Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Start date: July 2014
Phase: Phase 1
Study type: Interventional

This study is being conducted to test the possibility that a combination of three drugs, pomalidomide and everolimus with dexamethasone, may improve patient responses when compared with use of either drug alone, with dexamethasone in refractory/relapsed multiple myeloma.

NCT ID: NCT01794572 Terminated - Clinical trials for Multiple Myeloma in Relapse

Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma Relapse

TOMMY
Start date: April 24, 2013
Phase: Phase 1/Phase 2
Study type: Interventional

In Multiple Myeloma, an adult hematological malignancy, mainly located in the Bone Marrow (BM), dramatic recent progresses have been observed, thanks to new agents (proteasome inhibitors and IMIDs). However, at time of first relapse, high-dose therapy followed by Stem Cell Rescue (SCR) is frequently mandatory as a consolidation in minimal residual disease, to healthy patients under 65 yo, combining Melphalan (MPH) and/or Total Body Irradiation. Modern irradiation modalities are now available by the use of HI-ART Tomotherapy system to realize a Total Bone Marrow Irradiation (TBMI), in order both to limit the dose administered to Organ at Risk (lungs, oral cavity) and to focus efficacy on BM. In this phase-1 study, the conditioning regimen before SCR will combine a fixed high-dose MPH (140 mg/m²) and a dose escalated TBMI, so as to define its Maximal Tolerated Dose (MTD) and the Dose Limiting Toxicities (DLT). An extended cohort will further in a phase-2 setting.